ADARB1 and neoplasm: This bears two challenges: First, inhibitors that selectively block ADAR1 and not ADAR2 would need to be identified, and second, such drugs would need to be selectively delivered to tumor cells, which could be tackled by antibody or receptor-based coupling of ADAR1 inhibitors.